Kymera Therapeutics, Inc. cash flow to debt ratio of -283.14% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Kymera Therapeutics, Inc.'s free cash flow has decreased 13.02% from $-207.34M last year to $-234.34M, signaling decreasing performance

Kymera Therapeutics, Inc.'s debt to equity ratio is 0.05, which means that the company's assets are healthy financed, signaling financial stability.

Kymera Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.11 last year to 0.05 today, signaling strengthened financials

Kymera Therapeutics, Inc. has a net cash position, so leverage is healthy.

Kymera Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Kymera Therapeutics, Inc.'s profit margin has increased (-39.98%) in the last year from -475.57% to -285.41%, signaling increasing performance

Kymera Therapeutics, Inc.'s short-term assets of $871.21M exceed its short-term liabilities of $83.21M

Kymera Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Kymera Therapeutics, Inc.'s return on equity of -21.50%, is lower than 15.00%, indicating bad performance

Kymera Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Kymera Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Kymera Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Kymera Therapeutics, Inc. has negative free cash flow, indicating cash burn

Kymera Therapeutics, Inc.'s yearly earnings has decreased 39.11% since last year from $-223.86M to $-311.40M, signaling decreasing performance

Kymera Therapeutics, Inc.'s yearly revenue has decreased 16.72% since last year from $47.07M to $39.20M, signaling decreasing performance

ROIC -22.14% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Kymera Therapeutics, Inc.'s 3-year revenue CAGR of -5.75% is negative, indicating declining revenue over the past 3 years

Kymera Therapeutics, Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Kymera Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Kymera Therapeutics, Inc. has insufficient data to evaluate this check.

Kymera Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Kymera Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Kymera Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Kymera Therapeutics, Inc. has insufficient data to evaluate this check.

Kymera Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Kymera Therapeutics, Inc. has a price-to-book ratio of 7.08x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Kymera Therapeutics, Inc. has a price-to-sales ratio of 101.53x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue